Global Drug-Device Combination Market Set To Grow To $184bn By 2021

13 August 2018
Pharma

Visiongain has launched a new pharma report Global Drug-Device Combination Market 2017-2027: Drug Eluting Stents, Photosensitizers, Orthopaedic Products, Infusion Pumps, Wound Care Products, Transmucosal Products, Transdermal Patches, Hospital & Clinics, Ambulatory Surgical Centres, Emergency Service Centres, Home Care Settings

Combination products are being increasingly used in patients suffering from chronic disorders such as cardiac disease, cancer, diabetes, and multiple sclerosis among others. Owing to these products, a new dynamic has been initiated in the medical product development, regulatory approval as well as corporate interaction. Over the last decade, various regulatory agencies have developed numerous competences and regulations due to the rising integration of drugs and devices occurring in the latest generation of combination products.

The lead analyst of the report commented “the Drug-Device combination market is driven by initiatives from governments and NGOs in support of drug delivery implants, a rise in the usage of minimally invasive surgeries, technological innovations and advancements, and increasing prevalence of chronic disorders. However, regulatory challenges pertaining to recall of products due to adverse effects, technical challenges related to drug delivery and higher cost of the products are some of the factors hampering the growth of the Drug-Device combination market.”

Leading companies featured in the report include Medtronic, Boston Scientific Corporation, Stryker Corporation, Ethicon Inc, C.R. Bard Inc., Medline Industries Inc., Mylan Inc., Terumo Corporation, Pinnacle Biologics Inc., and W. L. Gore & Associates, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever